Publications:
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study
M Brewer, R Angioli, G Scambia, D Lorusso, C Terranova, P Benedetti Panici, F Raspagliesi, P Scollo, F Plotti, G Ferrandina, V Salutari, C Ricci, P Braly, R Holloway, M Method, M Madiyalakan, E Bayever, C Nicodemus
Gynecol Oncol;156(3):523-529, March 2020
Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients
A Battaglia, A Buzzonetti, M Fossati, G Scambia , A Fattorossi, MR Madiyalakan, YD Mahnke, C Nicodemus
Cancer Immunol Immunother, 69(3):383-397 March 2020
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma
C Lin, V Verma A Lazenby , QP Ly, LD Berim, JK Schwarz M Madiyalakan, CF Nicodemus, MA Hollingsworth, JL Meza, C Are, J Padussis, JL Grem
Am J Clin Oncol; 42(10):755-760, October 2019
The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer
P Braly, CF Nicodemus, C Chu, Y Collins, R Edwards, A Gordon, W McGuire, C Schoonmaker, MS, T Whiteside, LM Smith, M Method
J Immunother. Volume 32, Number 1, January 2009
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
JS Berek, P Taylor, W McGuire, LM Smith, BC Schultes, CF Nicodemus
J Clin Oncol Vol. 27:418-425, January 2009
CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer
JS Berek, PT Taylor, CF Nicodemus
J Immunother Volume 31, Number 2, February/March 2008
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
TG Ehlen, PJ Hoskins, D Miller, TL Whiteside, CF Nicodemus, BC Schultes, KD Swenerton
Int J Gynecol Cancer, Vol. 15, 1023-1034, 2005
Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer
JS Berek, PT Taylor, A Gordon, MJ Cunningham, N Finkler, J Orr Jr, S Rivkin, BC Schultes, TL Whiteside, CF Nicodemus
Journal of Clinical Oncology, Vol. 22, No. 17, September 2004
CA125- and Tumor-Specific T-cell Responses Correlate with Prolonged Survival in Oregovomab-treated Recurrent Ovarian Cancer Patients
A Gordon, BC Schultes, H Gallion, R Edwards, TL Whiteside, J Cermak, CF Nicodemus
Gynecologic Oncology 94, p.340-351, 2004
Immune responses to murine monoclonal antibody-B43.13 (oregovomab) correlate with prolonged survival of women with recurrent ovarian cancer
VJ Möbus, RP Baum, M Bolle, R Kreienberg, AA Noujaim, BC Schultes, CF Nicodemus
Am J Obstet Gynecol, Volume 189, Number 1, July 2003
Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo
A A Noujaim, BC Schultes, RP Baum, R Madiyalakan
Cancer Biotherapy & Radiopharmaceuticals, Volume 16, Number 3, 2001
Anti-idiotype Induction therapy:ani-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)
BC Schultes, RP Baum, A Niesen, AA Noujaim, R Madiyalakan
Cancer Immunol Immunother., Volume 46, 1998
Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA125 Murine Monoclonal Antibody B43.13
R Madiyalakan, TR Sykes, S Dharampaul, CJ Sykes, RP Baum, G Hor, AA Noujaim
Hybridoma, Volume 14, No. 2, 1995
The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer
P Braly, CF Nicodemus, C Chu, Y Collins, R Edwards, A Gordon, W McGuire, C Schoonmaker, MS, T Whiteside, LM Smith, M Method
J Immunother. Volume 32, Number 1, January 2009
Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 (oregovomab) in ovarian cancer patients
SA McQuarrie, RP Baum, A NIesen, R Madiyalakan, W Korz, TR Sykes, CJ Sykes, G Hör, AJB McEwan, AA Noujaim
Nuclear Medicine Communications, Volume 18, 1997
Activating Anti-Idiotypic Human Anti-Mouse Antibodies for Immunotherapy of Ovarian Carcinoma
RP Baum, A Niesen, A Hertel, A Nancy, H Hess, B Donnerstag, TR Sykes, CJ Sykes, MR Suresh, AA Noujaim, G Hor
CANCER Supplement, Volume 73, No. 3, February 1994
Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13 (Oregovomab)
RP Baum, AA Noujaim, A Nanci, V Moebus, A Hertel, A Niesen, B Donnerstag, T Sykes, G Boniface, G Hör
HYBRIDOMA Volume 12, Number 5, 1993
Posters:
Oregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort
J.J. Chan, S.H. Tan, T.W. Lim, T.J.Y. Tan, W.Y. Chay, E.H. Lim, L.T. Soh, S.L. Lim, J.W.K. Chia
ESMO 2018
A Randomized Phase II Study Assessing an Optimized Schedule of Oregovomab (O) anti-CA125 Vaccination with Carboplatin Paclitaxel (CP) Relative to CP alone in Front line Treatment of Optimally Cytoreduced Stage III/IV Ovarian Cancer (EOC)
G Ferrandina, PS Braly, C Terranova, V Salutari, C Ricci, F Raspagliesi, D Lorusso, PB Panici, P Scollo, F Plotti, M Brewer, MW Method, RW Holloway, M Madiyalakan, CF Nicodemus, SL Pecorelli, G Scambia, R Angioli
ASCO 2017
Translational Correlates of Indirect Antibody Immunization Using Scheduled Combination Therapy with Carboplatin-Paclitaxel Plus Oregovomab: A Randomized Study
A Battaglia, A Fattorossi, R Angioli, G Scambia, CF Nicodemus, M Madiyalakan
ESGO 2017
A Phase IbStudy of Indirect Immunization with Oregovomaband TLR3 Stimulation with Hiltonol® in Patients with Recurrent Platinum Resistant Ovarian Cancer (PROC)
R Holloway, S Temkin, S Gordon, C Nicodemus, M Madiyalakan ,W McGuire
ICGS 2019
OncoQuest Inc. 